CYP19A1 and breast cancer: This drug targets aromatase, an enzyme that converts androgen to estrogen, and is amply used in endocrine receptor-positive breast cancer, since it significantly reduces serum estrogen levels, decreasing the activation of estrogen and progesterone receptors in breast cancer [11].